Here, we extend analysis of the DOC-MEK study with reference to a MEK functional activity gene signature, developed as a prognostic and/or predictive biomarker of MEK functional activation across a variety of tumour types.19,20 We confirm no evidence of a predictive role for NRAS mutation status, but demonstrate that there is a correlation between response to treatment with docetaxel plus selumetinib and the MEK 6 gene signature score. The gene discussed is NRAS; the disease is neoplasm.